Corcept Therapeutics Incorporated (CORT) vs Summit Therapeutics Inc. (SMMT)

A side-by-side comparison of Corcept Therapeutics Incorporated and Summit Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Corcept Therapeutics Incorporated logo
CORT
Corcept Therapeutics Incorporated
$12.93B
$119.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Summit Therapeutics Inc. logo
SMMT
Summit Therapeutics Inc.
$13.74B
$17.23HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT

Total return — CORT vs SMMT

growth of $100 · dividends reinvested · last 10y
CORT +1837.0% (+34.5%/yr)SMMT +29.2% (+2.6%/yr)CORT compounded faster over this window
Log scale — wide-divergence pair
1101001k10kStart $10020182020202220242026$1,937$129
CORT SMMT

CORT vs SMMT: by the numbers

  • •SMMT is the larger company ($13.74B vs $12.93B market cap).
  • •CORT is profitable (6.61% net margin) while SMMT runs a net loss (0.00%).

Metrics side by side

Valuation

MetricCORTSMMT
P/E ratio284.69N/A
P/S ratio15.56N/A
P/B ratio18.3121.81
EV / EBITDA1453.11N/A
FCF yield0.83%N/A

Profitability

MetricCORTSMMT
Gross margin98.30%0.00%
Operating margin0.77%0.00%
Net margin6.61%0.00%
ROE7.78%-135.89%
ROIC0.87%-134.14%

Growth (annualized)

MetricCORTSMMT
Revenue CAGR (5Y)19.35%N/A
EPS CAGR (5Y)0.64%N/A
FCF CAGR (5Y)-4.40%N/A
Total return CAGR (5Y)43.90%28.09%

Frequently asked

Is CORT or SMMT more profitable?
CORT runs the higher net margin — CORT at 6.61% versus SMMT at 0.00%.
How have CORT and SMMT total returns compared?
Over the past 10 years, CORT delivered 33.70% and SMMT delivered 1.87% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CORT analysisFull SMMT analysisInteractive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratioCorcept Therapeutics ROESummit Therapeutics ROECorcept Therapeutics operating marginSummit Therapeutics operating marginCorcept Therapeutics revenue growthSummit Therapeutics revenue growthCorcept Therapeutics free cash flowSummit Therapeutics free cash flow

Corcept Therapeutics & Summit Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.